Small EVs From Adipose-Derived MSCs Modulate Epidermal Barrier and Inflammation Via Sphingosine-1-Phosphate Signaling Pathway.

Summary

ASC-derived sEVs are enriched in sphingolipids and in enzymes that synthesize ceramide and sphingosine-1-phosphate (S1P) while lacking hydrolytic enzymes, suggesting they raise ceramide/S1P in recipient cells. In AD-model keratinocytes, sEVs suppressed proinflammatory cytokines and restored differentiation, implicating S1P signaling in barrier repair and inflammation control.

Key Findings

• ASC-sEVs are enriched in free fatty acids, ceramide, and sphingomyelin and exhibit higher levels of ceramide and S1P synthetic enzymes compared to donor cells.
• Hydrolytic enzymes for ceramide and S1P are lower in ASC-sEVs, suggesting elevated ceramide/S1P in recipient cells.
• In AD-model human keratinocytes, ASC-sEVs suppressed pro-inflammatory cytokines and restored keratinocyte differentiation.

Clinical Implications

Supports development of topical sEV formulations targeting sphingolipid pathways for atopic dermatitis and barrier dysfunction, and highlights S1P signaling as a therapeutic axis.

Limitations

• Primarily in vitro with limited in vivo translational testing in this study.
• Donor variability and dosing/vehicle optimization for topical delivery were not fully addressed.

Future Directions

Test optimized topical sEV formulations in controlled in vivo models and early-phase trials, dissect S1P receptor subtype contributions, and assess long-term safety and manufacturing consistency.